应用Onclarity HPV扩展基因分型检测≥21岁ASC-US或LSIL细胞学女性高级别宫颈病变风险
该分析纳入Onclarity HPV试验基线期2807例≥21岁、ASC-US或LSIL细胞学女性,均转诊阴道镜/活检,按扩展基因分型计算与高级别宫颈病变相关的分层患病率和风险值。HPV 16在ASC-US和LSIL人群中≥CIN2风险最高;HPV 31、18、33/58、51和52构成中等风险带;HPV 35/39/68、45和56/59/66风险较低且低于立即阴道镜的基准阈值风险。结论支持对最低风险HPV基因型阳性的ASC-US或LSIL女性进行1年随访以排除立即阴道镜。
要点
- HPV 16在ASC-US和LSIL人群中≥CIN2风险最高。
- HPV 31、18、33/58、51和52构成中等风险带。
- HPV 35/39/68、45和56/59/66风险较低且低于立即阴道镜基准阈值。
核心结论
- HPV基因分型在≥21岁ASC-US和LSIL人群中识别出多个≥CIN3和≥CIN2风险带。
- 结果支持对最低风险HPV基因型阳性的ASC-US或LSIL女性进行1年随访以排除立即阴道镜。
研究设计与样本
- Onclarity HPV试验基线期分析,纳入2807例≥21岁、ASC-US或LSIL细胞学女性,均转诊阴道镜/活检。
- 基于扩展基因分型计算与高级别宫颈病变相关的分层患病率和风险值。
主要发现
- HPV 16在ASC-US和LSIL人群中≥CIN2风险最高。
- 其他13种基因型与≥CIN3和≥CIN2相关的风险在ASC-US和LSIL女性中略有差异,但HPV 31、18、33/58、51和52构成中等风险带。
- HPV 35/39/68、45和56/59/66在两种细胞学人群中风险相对较低,且低于立即阴道镜的基准阈值风险。
- 仅限21-24岁、≥25岁或≥30岁女性分析产生相似结果。
关键数值与推荐
- HPV 16在ASC-US和LSIL人群中≥CIN2风险最高。
- HPV 31、18、33/58、51和52构成中等风险带。
- HPV 35/39/68、45和56/59/66风险相对较低且低于立即阴道镜的基准阈值风险。
临床怎么用
- 作者认为结果支持对最低风险HPV基因型阳性的ASC-US或LSIL女性进行1年随访以排除立即阴道镜。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is growing interest in using human papillomavirus (HPV) genotyping as a risk-based triage approach for women with atypical squamous cells-undetermined significance (ASC-US) and low-grade squamous intraepithelial lesions (LSIL) cytology. METHODS: This analysis includes 2807 subjects with ASC-US or LSIL cytology, ≥21 years, from the baseline phase of the Onclarity HPV trial. All women were referred to colposcopy/biopsy. Hierarchical-ranked prevalence and risk values, associated with high-grade cervical disease, were calculated based on extended genotyping. RESULTS: HPV 16 carried the highest risk for cervical intraepithelial neoplasia grade 2 or worse (≥CIN2) in both the ASC-US and LSIL populations. Risk of ≥CIN3 and ≥CIN2 associated with the other 13 genotypes varied somewhat for women with ASC-US and LSIL, however, HPV 31, 18, 33/58, 51 and 52 appear to comprise an intermediate risk band. Risk associated with HPV 35/39/68, 45, and 56/59/66, in either cytology population, was relatively low and beneath the benchmark threshold risk for immediate colposcopy. Restricting the analysis to women 21-24 years, ≥25 years, or ≥30 years produced similar results. CONCLUSIONS: HPV genotyping identified multiple risk bands for ≥CIN3 and ≥CIN2 in the ≥21 year-old ASC-US and LSIL populations. These results support a 1-year follow-up period to preclude immediate colposcopy for ASC-US or LSIL women positive for the lowest-risk HPV genotypes.
引用
- Wright TC, Stoler MH, Parvu V, et al. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology. Gynecol Oncol. 2019. PMID: 31160073. doi:10.1016/j.ygyno.2019.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。